לברסט

Country: Израел

Језик: Хебрејски

Извор: Ministry of Health

Активни састојак:

LETROZOLE 2.5 MG

Доступно од:

RAFA LABORATORIES LTD

АТЦ код:

L02BG04

Фармацеутски облик:

FILM COATED TABLETS

Пут администрације:

PER OS

Произведен од:

SIEGFRIED GENERICS ( MALTA) LTD

Терапеутска група:

LETROZOLE

Терапеутске индикације:

Letrozole tablets are indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Датум одобрења:

2012-04-01